

Alembic Pharmaceuticals Limited

Familiarization Programmes for Independent Directors

| Name of the Independent Director | No. of programmes attended by the Independent Directors | | | No. of hours spent by the Independent Directors in such programmes | | |
|----------------------------------|---|--|------------------------|--|--|------------------------|
| | During the year (2025-26) | Cumulative till date (2014-15 Onwards) | Other relevant details | During the year (2025-26) | Cumulative till date (2014-15 Onwards) | Other relevant details |
| Mr. Ashok Kumar Barat | 1 | 10 | - | 00.15 | 13.45 | - |
| Mr. Jai Diwanji | 1 | 6 | - | 00.15 | 4.05 | - |
| Mr. Manish Kejriwal | 1 | 4 | - | 00.15 | 01:45 | - |
| Ms. Geeta Goradia | 1 | 2 | - | 00.45 | 00.45 | - |

Details of Familiarization Programmes imparted to Independent Directors:

| Date of the Programmes | Details of the Programmes |
|--------------------------------|---|
| 4 th February, 2015 | (a) The Roles, Rights, Responsibilities and Duties of Independent Directors. (b) The Company, Nature of Industry in the Company operates, business model of the Company. |
| 31 st July, 2015 | Research & Development Activities of the Company. |
| 27 th October, 2015 | Human Resources Activities of the Company. |
| 21 st January, 2016 | (a) US Operations (b) Strategy and Business Potential (c) Overview of Capex Plans |
| 25 th January, 2017 | Overview on on-going capital projects of the Company. |
| 3 rd May, 2017 | (a) CSR Activities carried out in F.Y. 2016-17 and proposed for F.Y. 2017-18. (b) Preparedness on GST. |
| 20 th July, 2017 | Proposed Growth Strategy, Capital Investments particularly in R & D and working of Joint Ventures (JVs). |
| 7 th November, 2017 | (a) US Business. (b) EU/ROW/Algeria. (c) Competitive Scenario and our strategy. (d) Orit Acquisition. |



ALEMBIC PHARMACEUTICALS LIMITED

| | |
|--------------------------------|--|
| | (e) Organogram & HR Practices. (f) Projects. (g) Timelines and tentative Mid Term Plan. |
| 31 st January, 2018 | (a) R & D and Market Trends. (b) Human Resources. (c) APL Consolidated Budget and IBU Budget. (d) Operations and Projects. |
| 16 th May, 2018 | IBU Business. |
| 26 th July, 2018 | (a) CSR Activities. (b) New process for all statutory compliances. (c) Recent amendments in Companies Act, 2013 & SEBI Regulations. |
| 22 nd October, 2018 | (a) Competitive scenario, strategy, capital expenditure and R & D for International Business. (b) Branded Business. |
| 22 nd January, 2019 | (a) IBU Budget. (b) Operations & Projects. |
| 8 th May, 2019 | Projects. |
| 24 th October, 2019 | Business Overview. |
| 23 rd April, 2020 | (a) Business Overview. (b) Covid-19 Precautions and Preparedness. |
| 29 th June, 2021 | (a) EHS practices & compliance status. (b) Legal Compliance Management System. |
| 10 th June, 2022 | (a) Overview of IBU Business Finance. (b) Outlook & Strategy for IBU Business. (c) IBU Business (EU & ROW markets). (d) API Business. (e) Quality Compliance. (f) Employee Engagement Survey. (g) Swot Analysis & Mid-Term Plan for IBU Business. (h) Budget & Strategy for India Branded Business. |
| 4 th August, 2023 | Overview of CSR Activities. |
| 6 th November, 2023 | Visit to Manufacturing Facilities at Karkhadi. |
| 7 th November, 2023 | a) Visit to Manufacturing Facilities at Panelav. b) Status updates and Business Overview. |
| 9 th May, 2024 | Overview of CSR Activities. |
| 8 th August, 2024 | (a) API Business (b) Highlights on EHS/ ESG |
| 3 rd February, 2025 | (a) IBU Business (EU & ROW markets) |
| 6 th May, 2025 | Overview of CSR Activities. |



ALEMBIC PHARMACEUTICALS LIMITED